Setback to Roche hopes for Tecentriq as fails key cancer trial

ZURICH (Reuters) - Roche's hopes of its Tecentriq immunotherapy catching up rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.